GT BIOPHARMA, INC. Payments for (Proceeds from) Investments
GT BIOPHARMA, INC. (GTBP) reported Payments for (Proceeds from) Investments of -$12.89 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromInvestments · last filed 2026-03-06
- GT BIOPHARMA, INC. payments for (proceeds from) investments for the quarter ending 2024-12-31 was -$1.00K.
- GT BIOPHARMA, INC. payments for (proceeds from) investments for the quarter ending 2024-09-30 was $1.00K.
- GT BIOPHARMA, INC. payments for (proceeds from) investments for the quarter ending 2024-06-30 was -$7.86M.
- GT BIOPHARMA, INC. payments for (proceeds from) investments for the quarter ending 2024-03-31 was -$5.03M, a 172.03% decline year-over-year.
- GT BIOPHARMA, INC. payments for (proceeds from) investments for fiscal 2024 was -$12.89M, a 741.76% decline from fiscal 2023.
- GT BIOPHARMA, INC. payments for (proceeds from) investments for fiscal 2023 was $2.01M.
- GT BIOPHARMA, INC. payments for (proceeds from) investments for fiscal 2022 was -$12.14M, a 152.71% decline from fiscal 2021.
- GT BIOPHARMA, INC. payments for (proceeds from) investments for fiscal 2021 was $23.04M.
| Period end | Payments for (Proceeds from) Investments 3 month | Payments for (Proceeds from) Investments 6 month | Payments for (Proceeds from) Investments 9 month | Payments for (Proceeds from) Investments 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | -$7.86M derived: sum of 3 quarters · filed 2026-03-06 | -$12.89M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2026-03-06 | -$7.86M derived: sum of 2 quarters · filed 2026-03-06 | -$12.89M 10-Q/A · filed 2026-03-06 | -$13.37M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | -$7.86M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2026-03-06 | -$12.89M 10-Q/A · filed 2026-03-06 | -$13.37M derived: sum of 3 quarters · filed 2026-03-06 | -$15.22M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | -$5.03M 10-Q · filed 2025-05-15 | -$5.51M derived: sum of 2 quarters · filed 2025-05-15 | -$7.36M derived: sum of 3 quarters · filed 2025-05-15 | -$10.01M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$478.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$2.32M derived: sum of 2 quarters · filed 2025-02-21 | -$4.98M derived: sum of 3 quarters · filed 2025-02-21 | $2.01M 10-K · filed 2025-02-21 |
| 2023-09-30 | -$1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$4.50M derived: sum of 2 quarters · filed 2024-11-14 | $2.49M 10-Q · filed 2024-11-14 | -$5.02M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $4.33M 10-Q · filed 2024-08-14 | -$3.17M derived: sum of 3 quarters · filed 2024-08-14 | -$3.20M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $6.99M 10-Q · filed 2024-05-15 | -$517.00K derived: sum of 2 quarters · filed 2024-05-15 | -$542.00K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$7.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$7.53M derived: sum of 2 quarters · filed 2024-03-26 | -$12.14M 10-K · filed 2024-03-26 | |
| 2022-09-30 | -$25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$4.64M 10-Q · filed 2023-11-01 | ||
| 2022-06-30 | -$4.61M 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | -$2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $23.04M 10-K · filed 2023-03-30 | ||
| 2021-09-30 | $26.03M 10-Q · filed 2022-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |